Lotus Pharmaceutical (1795) Stock Overview
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 1795 from our risk checks.
1795 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lotus Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$211.00 |
| 52 Week High | NT$294.50 |
| 52 Week Low | NT$172.50 |
| Beta | -0.013 |
| 1 Month Change | 9.04% |
| 3 Month Change | -4.52% |
| 1 Year Change | -22.14% |
| 3 Year Change | 37.01% |
| 5 Year Change | 161.79% |
| Change since IPO | 70.85% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Low P/E
Mar 29
Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence
Strategic acquisitions and alliances are bolstering Lotus Pharmaceutical's growth and diversification, particularly in Southeast Asia.Lotus Pharmaceutical (TWSE:1795) Seems To Use Debt Quite Sensibly
Feb 24Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings
Dec 04Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 16Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem
Nov 14Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden
Oct 23Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next
Aug 14Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)
Jul 18Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?
Apr 24Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price
Apr 09Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals
Mar 22Shareholder Returns
| 1795 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 13.1% | -0.5% | 2.3% |
| 1Y | -22.1% | 18.8% | 15.4% |
Return vs Industry: 1795 underperformed the TW Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: 1795 underperformed the TW Market which returned 15.4% over the past year.
Price Volatility
| 1795 volatility | |
|---|---|
| 1795 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 1795 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1795's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | n/a | Petar Vazharov | www.lotuspharm.com.tw |
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services.
Lotus Pharmaceutical Co., Ltd. Fundamentals Summary
| 1795 fundamental statistics | |
|---|---|
| Market cap | NT$50.49b |
| Earnings (TTM) | NT$4.86b |
| Revenue (TTM) | NT$19.12b |
Is 1795 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1795 income statement (TTM) | |
|---|---|
| Revenue | NT$19.12b |
| Cost of Revenue | NT$7.67b |
| Gross Profit | NT$11.45b |
| Other Expenses | NT$6.59b |
| Earnings | NT$4.86b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.49 |
| Gross Margin | 59.89% |
| Net Profit Margin | 25.43% |
| Debt/Equity Ratio | 55.9% |
How did 1795 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/24 14:13 |
| End of Day Share Price | 2025/09/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lotus Pharmaceutical Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| MingXiang Chang | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |